Screener
West Pharmaceutical Services WST Payments for finance leases
Payments for finance leases at other companies
Other financials
Where this comes from
Reported directly by West Pharmaceutical Services in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.
The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000105770-26-000099
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from financing activities: | ||
| Borrowings under revolving credit agreements | 50.0 | — |
| Repayments under revolving credit agreements | (50.0) | — |
| Principal repayments on finance leases | (0.7) | (0.5) |
| Excise tax payments | (0.8) | (4.2) |
| Dividend payments | (31.5) | (30.3) |
| Proceeds from stock-based compensation awards | 12.4 | 6.0 |
| Employee stock purchase plan contributions | 3.9 | 3.6 |
Item 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is West Pharmaceutical Services's payments for finance leases?
- West Pharmaceutical Services (WST) reported payments for finance leases of $400K in Q2 2026.
- How has West Pharmaceutical Services's payments for finance leases changed year-over-year?
- West Pharmaceutical Services's payments for finance leases increased by 33.3% year-over-year, from $300K to $400K.
- What does payments for finance leases mean?
- Principal payments on finance lease obligations, reducing the lease liability on the balance sheet.
Ask your AI about West Pharmaceutical Services's payments for finance leases.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude